TrialInvestigational new drugs2015

First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies.

Åke Berglund et al.PubMed ↗Publisher ↗

No numbers read from the abstract.